危重症成人患者的个体化抗癫痫发作药物治疗
本综述讨论危重症成人患者抗癫痫发作药物的精准医学应用。由于该人群给药信息匮乏,治疗药物监测有助于确定个体化治疗范围并辅助临床决策。利用药代动力学、肝脏代谢和癫痫病因相关的药物基因组学信息可能通过个体化治疗提高安全性和有效性。
要点
- 危重症患者抗癫痫药物给药信息匮乏,治疗药物监测可辅助确定个体治疗范围。
- 药代动力学、肝脏代谢和癫痫病因相关的药物基因组学信息可用于个体化治疗。
- 需开展临床实施研究和生物标志物识别研究以优化危重症患者抗癫痫治疗。
核心结论
- 精准医学可能对危重症成人患者的抗癫痫发作药物治疗产生显著影响。
- 治疗药物监测和药物基因组学信息可用于个体化抗癫痫治疗以提高安全性和有效性。
研究设计与样本
- 本综述讨论危重症成人患者抗癫痫发作药物治疗的现有文献并提供精准医学应用的未来展望。
主要发现
- 危重症患者与门诊人群相比存在不同的治疗问题,使选择最佳抗癫痫药物及在正确时间和正确剂量给药具有挑战性。
- 危重症患者抗癫痫药物给药信息匮乏,治疗药物监测是确定每位患者个体治疗范围并辅助临床决策的有用工具。
- 利用药代动力学、肝脏代谢和癫痫病因相关的药物基因组学信息可能通过个体化治疗提高安全性和有效性。
临床怎么用
- 对危重症成人患者使用治疗药物监测以定义个体治疗范围并辅助临床决策。
- 利用药代动力学、肝脏代谢和癫痫病因相关的药物基因组学信息进行个体化治疗。
局限性
- 危重症患者抗癫痫药物给药信息匮乏。
- 需要评估药物基因组学信息在即时检测中临床实施的研究以及识别生物标志物的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision medicine has the potential to have a significant impact on both drug development and patient care. It is crucial to not only provide prompt effective antiseizure treatment for critically ill patients after seizures start but also have a proactive mindset and concentrate on epileptogenesis and the underlying cause of the seizures or seizure disorders. Critical illness presents different treatment issues compared with the ambulatory population, which makes it challenging to choose the best antiseizure medications and to administer them at the right time and at the right dose. Since there is a paucity of information available on antiseizure medication dosing in critically ill patients, therapeutic drug monitoring is a useful tool for defining each patient's personal therapeutic range and assisting clinicians in decision-making. Use of pharmacogenomic information relating to pharmacokinetics, hepatic metabolism, and seizure etiology may improve safety and efficacy by individualizing therapy. Studies evaluating the clinical implementation of pharmacogenomic information at the point-of-care and identification of biomarkers are also needed. These studies may make it possible to avoid adverse drug reactions, maximize drug efficacy, reduce drug-drug interactions, and optimize medications for each individual patient. This review will discuss the available literature and provide future insights on precision medicine use with antiseizure therapy in critically ill adult patients.
引用
- Almohaish S, Cook AM, Brophy GM, et al. Personalized antiseizure medication therapy in critically ill adult patients. Pharmacotherapy. 2023. PMID: 36999346. doi:10.1002/phar.2797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。